瑞加诺生负荷SPECT心肌灌注显像中副作用与血流动力学反应的性别差异
该研究纳入858例连续接受瑞加诺生负荷SPECT心肌灌注显像的患者,前瞻性评估副作用并记录心率与血压,经1:1倾向性匹配后形成279对男女配对。女性任何副作用、胸痛、胃肠道不适、头晕和头痛发生率显著高于男性,女性心率反应更高而男性收缩压反应更低。性别与瑞加诺生总体副作用和心率反应差异独立相关。
要点
- 女性瑞加诺生负荷后任何副作用发生率显著高于男性(71% vs 58%,p=0.002)。
- 女性胸痛、胃肠道不适、头晕、头痛发生率均显著高于男性。
- 女性心率反应中位数更高(41% vs 34%,p=0.001),男性收缩压反应中位数更低(-3% vs 0%,p=0.02)。
核心结论
- 性别与瑞加诺生总体副作用及心率反应差异独立相关。
- 这些观察可能对管理和预后分别具有潜在重要意义。
研究设计与样本
- 初始人群为858例连续在本机构接受瑞加诺生负荷SPECT心肌灌注显像的患者,前瞻性评估并分类六类副作用,记录给药前后心率和血压。
- 以性别为因变量,年龄、BMI、糖尿病、高血压、吸烟、冠心病、LVEF、基线收缩压和舒张压及心率、试验期间使用心血管活性药物、异常MPI扫描为自变量进行1:1倾向性匹配,形成279对异性配对人群进行研究。
主要发现
- 与男性相比,女性任何副作用发生率显著更高(71% vs 58%,p=0.002)。
- 女性胸痛(23% vs 12%,p<0.001)、胃肠道不适(20% vs 12%,p=0.01)、头晕(12% vs 5%,p=0.002)、头痛(20% vs 13%,p=0.03)发生率均显著高于男性。
- 呼吸困难和其他副作用发生率在男女间相似。
- 女性心率反应中位数高于男性(41%(-8, 127)vs 34%(-5, 106),p=0.001)。
- 男性收缩压反应中位数低于女性(-3%(-27, 48)vs 0%(-36, 68),p=0.02)。
临床怎么用
- 临床使用瑞加诺生负荷MPI时应关注女性患者更高的总体副作用及胸痛、胃肠道不适、头晕、头痛风险。
- 解读瑞加诺生负荷试验血流动力学反应时需考虑性别差异,女性心率反应更高而男性收缩压反应更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate differences in side-effects and hemodynamic response between men and women undergoing regadenoson-stress SPECT myocardial perfusion imaging (MPI). METHODS: The initial population of the study included 858 consecutive patients who underwent regadenoson-stress MPI at our institution. These patients underwent prospective assessment and classification of regadenoson-induced side-effects in six categories and recording of heart rate (HR) and blood pressure (BP) before and after regadenoson administration. From this initial population, after adjustment with 1:1 propensity matching using gender as the dependent variable and age, BMI, diabetes mellitus, hypertension, smoking, presence of coronary artery disease, LVEF, baseline systolic and diastolic blood pressure (BP) and HR, on-going use of cardio-active medications during test, and abnormal MPI scan as independent variables, a population of 279 pairs of opposite gender was formed and studied. RESULTS: Compared with men, women had a significantly higher rate of any side-effect (71% vs. 58%, p = 0.002), chest pain (23% vs. 12%, p < 0.001), gastrointestinal discomfort (20% vs. 12%, p = 0.01), dizziness (12% vs. 5%, p = 0.002), and headache (20% vs. 13%, p = 0.03) and similar rates of dyspnea and other side-effects. Women demonstrated a higher median HR-response compared with men (41% (- 8, 127) vs. 34% (- 5, 106), p = 0.001) while men demonstrated a lower median systolic BP response (- 3% (- 27, 48) vs. 0% (- 36, 68), p = 0.02) compared with women. CONCLUSIONS: Gender is independently associated with a differential response to regadenoson with regard to overall side-effects and HR-response. These observations have the potential of important management and prognostic implications respectively.
引用
- Katsikis A, Kyrozi E, Manira V, et al. Gender-related differences in side-effects and hemodynamic response to regadenoson in patients undergoing SPECT myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2019. PMID: 31414207. doi:10.1007/s00259-019-04463-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。